Post‐thrombotic syndrome · people requiring treatment for chronic DVT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in adverse events compared with BMP plus placebo (moderate certainty).
1 finding from 1 review
Major bleeding · people requiring treatment for acute DVT
1 finding from 1 review
Pulmonary embolism · people requiring treatment for acute DVT
1 finding from 1 review
Mortality ‐ early and intermediate · people requiring treatment for acute DVT
1 finding from 1 review
Post‐thrombotic syndrome · people requiring treatment for acute DVT
It is very uncertain whether acute DVT ‐ antiplatelet agents plus BMP changes post‐thrombotic syndrome compared with BMP alone (very low certainty).
1 finding from 1 review
Adverse events · people requiring treatment for acute DVT
It is very uncertain whether acute DVT ‐ antiplatelet agents plus BMP changes adverse events compared with BMP alone (very low certainty).
1 finding from 1 review
Recurrent VTE ‐ early and intermediate · people requiring treatment for chronic DVT
It is very uncertain whether chronic DVT ‐ antiplatelet agents plus BMP changes recurrent VTE ‐ early and intermediate compared with BMP alone (very low certainty).
1 finding from 1 review
Major bleeding · people requiring treatment for chronic DVT
1 finding from 1 review
Pulmonary embolism · people requiring treatment for chronic DVT
1 finding from 1 review
All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE
1 finding from 1 review
All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE
It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes all‐cause mortality (90‐day) compared with standard intravenous heparinisation (very low certainty).
1 finding from 1 review
Treatment‐associated major haemorrhage ( · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Treatment‐associated minor haemorrhage ( · people with intermediate‐risk (submassive) APE
It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes treatment‐associated minor haemorrhage ( compared with standard intravenous heparinisation (very low certainty).
1 finding from 1 review
Recurrent APE requiring retreatment or change to a different APE treatment ( · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Length of hospital stay · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Quality of life  · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Risk of HAE attacks (during · children or adults with Types I or II HAE
Avoralstat showed no clear difference in risk of HAE attacks (during compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review